Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0SLRYU |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | h20F3ec |
|||||
| Antigen Name | SLAMF6 |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
SGN-CD352A [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible participants must have IMWG-defined multiple myeloma requiring systemic therapy, age ≥18 years, ECOG 0-1, life expectancy >3 months, ≥2 prior lines of therapy (including IMiD and PI), measurable disease, adequate organ function, and negative pregnancy test. Key exclusions include recent malignancies (past 3 years), active CNS disease, severe infections, HIV/HBV/HCV positivity, prior allogeneic transplant, significant pulmonary/cardiovascular comorbidities, or pregnancy/breastfeeding.
Click to Show/Hide
|
||||
| Administration Dosage |
On the first day of each 28-day cycle, SGN-CD352A will be given IV. The dose of SGN-CD352A is different in each cohort of the study, with the lowest dose in Cohort -1 (4 mcg/kg) and the highest in Cohort 6 (65 mcg/kg). Patients can only be enrolled into a higher dose level arm if lower doses have proven safe.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02954796 | Clinical Status | PHASE1 | ||
| Clinical Description |
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
|
||||
| Primary Endpoint |
The study assesses safety through comprehensive evaluation of adverse events (type, incidence, severity, seriousness, and relatedness) monitored for 1 month post-treatment, along with dose-limiting toxicities during the first 28-day cycle.
|
||||
| Other Endpoint |
Efficacy outcomes include overall survival, progression-free survival, duration of response (both objective and complete), and response rates (ORR/CR) tracked for approximately 3 years, complemented by immunogenicity analysis (antitherapeutic antibodies) and pharmacokinetic profiling of SGN-CD352A and metabolites over the same period.
|
||||
References